Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) confirmed on Wednesday that it will continue developing efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) for idiopathic inflammatory myopathies (IIM) after positive Phase 2 data.

The drug demonstrated a significant treatment effect in reducing muscle weakness and improving overall disease activity.

The Phase 3 ALKIVIA study will enrol patients across three IIM subtypes: immune-mediated necrotising myopathy, anti-synthetase syndrome, and dermatomyositis.

Efgartigimod SC, a first-in-class neonatal Fc receptor (FcRn) blocker, has the potential to become the first targeted therapy for IIM patients, offering a new treatment option beyond current standard-of-care therapies.